"False"
Umeå universitet
printicon
Huvudmenyn dold.

Andreas Josefsson

Forskar om biomarkörer för individanpassad behandling samt behandlingsbara mekanismer för spridd prostatacancer.

Vetenskaplig meritering: Docent

Kontakt

E-post
andreas.josefsson@umu.se
Telefon

Verksam vid

Anknytning
Biträdande universitetslektor, kombinerad med klinisk tjänstgöring vid Institutionen för diagnostik och intervention Enhet: Urologi och andrologi
Plats
5A, Målpunkt H62, Norrlands universitetssjukhus Umeå universitet, 901 85 Umeå
Anknytning
Anknuten som övrig/annan befattning till Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)
Plats
Umeå universitet, 901 87 Umeå
Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition
BMC Cancer, BioMed Central (BMC) 2024, Vol. 24, (1)
Cheng, Tuck Seng; Noor, Urwah; Watts, Eleanor; et al.
Performance of 4Kscore as a reflex test to prostate-specific antigen in the GÖTEBORG-2 prostate cancer screening trial
European Urology
Josefsson, Andreas; Månsson, Marianne; Kohestani, Kimia; et al.
Acoustic enrichment of heterogeneous circulating tumor cells and clusters from metastatic prostate cancer patients
Analytical Chemistry, American Chemical Society (ACS) 2024, Vol. 96, (18) : 6914-6921
Magnusson, Cecilia; Augustsson, Per; Undvall Anand, Eva; et al.
Research protocol for an observational health data analysis on the adverse events of systemic treatment in patients with metastatic hormone-sensitive prostate cancer: big data analytics using the PIONEER platform
European Urology Open Science, Elsevier 2024, Vol. 63 : 81-88
Rajwa, Pawel; Borkowetz, Angelika; Abbott, Thomas; et al.
Molekylära subtyper och avancerad prostatacancer: nya möjligheter för anpassad behandling: [Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer]
Läkartidningen, Läkartidningen Förlag AB 2024, Vol. 121
Wikström, Pernilla; Bergh, Anders; Josefsson, Andreas; et al.
Effects on serum hormone concentrations after a dietary phytoestrogen intervention in patients with prostate cancer: a randomized controlled trial
Nutrients, MDPI 2023, Vol. 15, (7)
Ahlin, Rebecca; Nørskov, Natalja P.; Nybacka, Sanna; et al.
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
Acta Oncologica, Taylor & Francis 2023, Vol. 62, (4) : 372-380
Josefsson, Andreas; Jellvert, Åsa; Holmberg, Erik; et al.
Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer
Acta Oncologica, Taylor & Francis 2023, Vol. 6212 : 1698-1706
Spyratou, Vasiliki; Freyhult, Eva; Bergh, Anders; et al.
The effect of a phytoestrogen intervention and impact of genetic factors on tumor proliferation markers among Swedish patients with prostate cancer: study protocol for the randomized controlled PRODICA trial
Trials, BioMed Central (BMC) 2022, Vol. 23, (1)
Ahlin, Rebecca; Nybacka, Sanna; Josefsson, Andreas; et al.
Osteoclasts directly influence castration-resistant prostate cancer cells
Clinical and Experimental Metastasis, Springer Nature 2022, Vol. 39, (5) : 801-814
Huang, Junchi; Freyhult, Eva; Buckland, Robert; et al.
Little support for a protective effect of ADT against COVID-19
Scandinavian journal of urology, Taylor & Francis Group 2022, Vol. 56, (2) : 112-113
Josefsson, Andreas
Prostate specific antigen and biopsy contamination in the Göteborg-1 randomized, population-based, prostate cancer screening trial
Journal of Urology, American urological association 2022, Vol. 208, (5) : 1018-1027
Stinesen Kollberg, K.; Holmberg, E.; Josefsson, Andreas; et al.
Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study
BMJ Open, BMJ Publishing Group Ltd 2022, Vol. 12, (2)
Sund, Malin; Fonseca-Rodríguez, Osvaldo; Josefsson, Andreas; et al.
Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C
Molecular Oncology, John Wiley & Sons 2022, (4)
Thysell, Elin; Köhn, Linda; Semenas, Julius; et al.
Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93.
European Urology, Elsevier 2022, Vol. 81, (5) : e124-e125
Welen, Karin; Rosendal, Ebba; Freyhult, Eva; et al.
Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients
European Urology, Elsevier 2022, Vol. 81, (6) : e143-e144
Welén, Karin; Rosendal, Ebba; Freyhult, Eva; et al.
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
European Urology, Elsevier 2022, Vol. 81, (3) : 285-293
Welén, Karin; Rosendal, Ebba; Gisslén, Magnus; et al.
Epithelial and stromal characteristics of primary tumors predict the bone metastatic subtype of prostate cancer and patient survival after androgen-deprivation therapy
Cancers, MDPI 2022, Vol. 14, (21)
Wikström, Pernilla; Halin Bergström, Sofia; Josefsson, Andreas; et al.
High-grade tumours promote growth of other less-malignant tumours in the same prostate
Journal of Pathology, John Wiley & Sons 2021, Vol. 253, (4) : 396-403
Halin Bergström, Sofia; Rudolfsson, Stina H.; Lundholm, Marie; et al.
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
Trials, BioMed Central 2021, Vol. 22, (1)
Welén, Karin; Överby, Anna K.; Ahlm, Clas; et al.
Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens
The Prostate, John Wiley & Sons 2020, Vol. 80, (2) : 214-224
Bovinder Ylitalo, Erik; Thysell, Elin; Thellenberg-Karlsson, Camilla; et al.
Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells
Cancers, MDPI 2020, Vol. 12, (1)
Josefsson, Andreas; Larsson, Karin; Freyhult, Eva; et al.
The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS)
European Urology, Elsevier 2019, Vol. 76, (4) : 461-466
Bratt, Ola; Holmberg, Erik; Andrén, Ove; et al.
Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
Modern Pathology, Vol. 32, (9) : 1310-1319
Hammarsten, Peter; Josefsson, Andreas; Thysell, Elin; et al.
AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer
Acta Oncologica, Taylor & Francis Group 2019, Vol. 58, (11) : 1660-1664
Josefsson, Andreas; Damber, Jan-Erik; Welén, Karin
Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres
Scandinavian journal of urology, Taylor & Francis 2019, Vol. 53, (5) : 304-311
Kohestani, Kimia; Wallström, Jonas; Dehlfors, Niclas; et al.
Circulating tumor cells mirror bone metastatic phenotype in prostate cancer
Oncotarget, Vol. 9, (50) : 29403-29413
Josefsson, Andreas; Larsson, Karin; Månsson, Marianne; et al.
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer
The Prostate, Wiley-Blackwell 2017, Vol. 77, (8) : 849-858
Josefsson, Andreas; Linder, Anna; Flondell Site, Despina; et al.
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide
EJNMMI Research, Springer 2016, Vol. 6
Anand, Aseem; Morris, Michael J.; Larson, Steven M.; et al.
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome
European Journal of Cancer, Vol. 50, (10) : 1829-1835
Tidehag, Viktor; Hammarsten, Peter; Egevad, Lars; et al.
Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1831, (10) : 1579-1587
Fowler, Christopher J.; Josefsson, Andreas; Thors, Lina; et al.
Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy
Human Pathology, Vol. 44, (3) : 310-319
Mirtti, Tuomas; Leiby, Benjamin E.; Abdulghani, Junaid; et al.
Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression
PLOS ONE, Vol. 7, (10) : e47994-
Hammarsten, Peter; Cipriano, Mariateresa; Josefsson, Andreas; et al.
Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance
Scandinavian Journal of Urology and Nephrology, Informa Healthcare 2012, Vol. 46, (4) : 247-257
Josefsson, Andreas; Wikström, Pernilla; Egevad, Lars; et al.
Prognostic markers in prostate cancer: studies of a watchful waiting cohort with long follow up
Umeå University medical dissertations, 1472
Josefsson, Andreas
Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome
American Journal of Pathology, Vol. 179, (4) : 1961-1968
Josefsson, Andreas; Adamo, Hani; Hammarsten, Peter; et al.
LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer.
International Journal of Cancer, Wiley 2011, Vol. 128, (12) : 2843-2852
Thomasson, Marcus; Wang, Baofeng; Hammarsten, Peter; et al.
Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Clinical Cancer Research, Vol. 16, (4) : 1245-1255
Hammarsten, Peter; Karalija, Amar; Josefsson, Andreas; et al.
Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival
PLOS ONE, Vol. 5, (5) : e10747-
Hägglöf, Christina; Hammarsten, Peter; Josefsson, Andreas; et al.
A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer
European Journal of Cancer, Vol. 45, (1) : 174-182
Chung, Sui Chu; Hammarsten, Peter; Josefsson, Andreas; et al.
Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment
European Urology, Vol. 48, (4) : 577-583
Josefsson, Andreas; Wikström, Pernilla; Granfors, Torvald; et al.
Excellent cabazitaxel response in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of resistance development by anti-androgens
Bovinder Ylitalo, Erik; Thysell, Elin; Thellenberg-Karlsson, Camilla; et al.
The microRNA landscape of prostate cancer bone metastases and the role of miRNA-375 in modulating phenotypic characteristics of metastatic cells
Järemo, Helena; Semenas, Julius; Halin Bergström, Sofia; et al.
Visa publikationer i DiVA

Forskargrupper

Forskningsledare
Andreas Josefsson prostate cancer group

Forskningsprojekt

1 september 2023
SPRINTR
1 januari 2022
PAMP (PSMA, Acetate and Multiparametric MRI for Prostate cancer)
1 augusti 2020 till 31 december 2027
APACA-studien: Kan CTC fungera som ett surrogat för biopsier från metastaser?
8 juni 2020 till 31 maj 2022
COVIDENZA: Prostatacancerbehandling mot Covid-19
1 januari 2009 till 31 december 2025
SPCG-14
Andreas Josefsson: Prostatacancer- ska den alltid behandlas?

Ofarlig prostataförstoring behöver inte behandlas - det gäller att hitta den prostatacancer som är farlig.

Världsunik forskning kring prostatacancer

Det finns olika subtyper av prostatacancer och det kan få betydelse för vilken behandling som är bäst.

Debattartikel i Dagens Medicin

Vi behöver ett nätverk för kliniska studier inför nästa hälsokris skriver 12 läkare.

Artikel i Läkartidningen

Molekylära subtyper och avancerad prostatacancer. Nya möjligheter för anpassad behandling.